about
Gout. Easy to misdiagnoseDiagnosis and management of goutGout Classification Criteria: Update and ImplicationsEpidemiology, risk factors, and lifestyle modifications for goutEpidemiology of gout.The prevalence of hyperuricemia in China: a meta-analysis.Gout: a review of nonmodifiable and modifiable risk factors.Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.Revisiting the pathogenesis of podagra: why does gout target the foot?Epidemiology and management of gout in Taiwan: a nationwide population study.The epidemiology of uric acid and fructose.Clinical applications of drug desensitization in the Asia-Pacific region.Gout epidemiology: results from the UK General Practice Research Database, 1990-1999.The SLC2A9 nonsynonymous Arg265His variant and gout: evidence for a population-specific effect on severityA cohort study comparing cardiovascular risk factors in rural Maori, urban Maori and non-Maori communities in New Zealand.Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis.Folic acid reverses uric acid crystal-induced surface OAT1 internalization by inhibiting RhoA activity in uric acid nephropathy.Sleep Apnea and the Risk of Incident Gout: A Population-Based, Body Mass Index-Matched Cohort Study.Gout. Hyperuricemia and cardiovascular disease: how strong is the evidence for a causal link?The epidemiology and treatment of goutThe waist circumference-adjusted associations between hyperuricemia and other lifestyle-related diseases.Systematic review of rheumatic disease phenotypes and outcomes in the Indigenous populations of Canada, the USA, Australia and New Zealand.Drug treatment of hyperuricemia to prevent cardiovascular outcomes: are we there yet?Systematic review of the prevalence of gout and hyperuricaemia in Australia.The global burden of gout: estimates from the Global Burden of Disease 2010 study.Determinants of the prevalence of gout in the general population: a systematic review and meta-regression.Management of gout in general practice--a systematic review.Association between ABCG2 Q141K polymorphism and gout risk affected by ethnicity and gender: a systematic review and meta-analysis.Prevalence and incidence of gout in Korea: data from the national health claims database 2007-2015.Uric acid crystal could inhibit Numb-induced URAT1 lysosome degradation in uric acid nephropathy.The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012.Hyperuricaemia and gout in New Zealand rural and urban Māori and non-Māori communities.Contemporary epidemiology of gout and hyperuricemia in community elderly in Beijing.The prevalence of gout in an urban area of Izmir, Turkey: a population-based epidemiological study.Assessment of genetic polymorphisms associated with hyperuricemia or gout in the Hmong.High Serum Uric Acid Levels Are Associated with All-Cause and Cardiovascular, but Not Cancer, Mortality in Elderly Adults.Comprehensive dietary education in treated gout patients does not further improve serum urate.Fucoidan elevates surface organic cation transporter 2 expression via upregulation of protein kinase A in uric acid nephropathy.Role of the urate transporter SLC2A9 gene in susceptibility to gout in New Zealand Māori, Pacific Island, and Caucasian case-control sample sets.Magnetic resonance imaging diagnosis of gouty tophi in a man with gout and Bartter's syndrome.
P2860
Q24527301-429EA4A9-F5BA-44BE-B10E-D9F7FDEF72D3Q24546235-23B341D2-5FDE-420D-9F53-688DF5E2150BQ26747158-639BE981-9B09-489D-B98B-EA52538B013CQ28199023-A57BCD01-BD81-412C-8B41-3DBC46D1F13DQ33993424-8EC68CB3-D23A-4078-BBCB-1AEBE09A487FQ34059953-C01EED40-50FA-4C1A-9932-ED102CB9FC58Q34609600-E8CAEA1F-52BE-4862-B0F0-EB91840E4AF3Q34986307-392989C6-3BDA-48F8-B6E2-B7A2D1C39DC6Q35052925-5BB41322-2ED1-4262-99AE-68CA3E0070DAQ35127836-438723FB-DC9C-4623-B0A4-E108E8DD1D37Q35393502-4DB616A7-68D5-4830-BD7C-AEDE37E4163FQ35502326-C2B2D21A-6F4B-44F2-95CB-DD80F0E362BDQ35555160-9C11116E-2046-486B-AC46-B0FF3C937A6CQ35557878-B8620B66-FA3A-45E7-8592-18FDD1630EF0Q36045026-5EB67771-F611-4B62-99A2-334130EEFB19Q36310374-F7E766AA-9715-4277-96E3-3E2E357BEB2CQ36624084-C4B34E21-0688-4BF5-BA1F-4C8780D35650Q36766969-0BD3191E-ACBA-4D71-B75C-EEE836E70C8AQ37350881-0154B368-EFF0-43B9-88A5-9B9A12EF4311Q37358257-148F602A-6420-4CC4-B06C-19F6B4800767Q37635299-C8C3F828-0EAB-4CCC-A49E-E3E541F1FCF6Q37709963-AF8168E2-1FA3-4219-8E77-50B3B7338E6EQ37972015-8151688D-0B11-476B-9DA6-578A59341989Q38135856-A8C784FC-1980-49B5-AD05-A61EF50ED7F3Q38192917-C46A3ED3-8BDD-4D9C-AC44-CD1E5D4D3399Q38234234-C114FEB0-FD54-4F8D-84CC-684B2D38FC5CQ38249921-763DED4E-8B04-4D2F-B579-C305884C0FBAQ38339494-506FCAC7-8F70-4783-87A0-63FE578EE4EBQ38662799-ADF374EA-C51F-41F7-9AD0-1A4863EEC62DQ38899720-F72D2E9F-B6C4-43BA-98F1-60DD66A63562Q39046892-ADABB03B-F9A1-4FD9-9861-AB3E777CECE3Q40083247-8C8D13A5-48F7-4748-9CB2-43E9BE43BC90Q40143299-7617906B-C753-472E-A2DA-BAFDDE671EBEQ40171932-574F52B8-E408-4553-92AF-471FF5DF2CFAQ41209052-3422E1AA-8F60-476A-9555-9AF35D6ED40BQ41479228-6126A796-8C52-4875-ABE1-179130A21EF2Q41704527-A7EEFBC2-398F-4C79-A741-F31CFB0130DAQ43110902-AC764B7F-BBC9-4808-8A29-4C7C8CED7FF2Q43251977-2DEC9484-7A05-475C-87D8-E985B5415B6BQ44202551-D271ABFD-B6FE-473F-AEF3-FAA9D3C72F8A
P2860
description
1997 nî lūn-bûn
@nan
1997 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Gout is on the increase in New Zealand.
@ast
Gout is on the increase in New Zealand.
@en
type
label
Gout is on the increase in New Zealand.
@ast
Gout is on the increase in New Zealand.
@en
prefLabel
Gout is on the increase in New Zealand.
@ast
Gout is on the increase in New Zealand.
@en
P2093
P2860
P356
P1476
Gout is on the increase in New Zealand.
@en
P2093
Robertson MC
Stansfield SA
P2860
P356
10.1136/ARD.56.1.22
P407
P577
1997-01-01T00:00:00Z